Peptides & Amino Acids

Recombinant Human Tissue Inhibitor of Metalloproteinases 3 (TIMP3), Western Blot Control

Recombinant Human Tissue Inhibitor of Metalloproteinases 3 (TIMP3), Western Blot Control

Recombinant Human Tissue Inhibitor of Metalloproteinases 3 (TIMP3), Western Blot Control

Recombinant Human Tissue Inhibitor of Metalloproteinases 3 (TIMP3), Western Blot Control

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

[Glu2]-TRH tripeptide – pGlu-Glu-Pro-NH2 (CAS: 85541-78-2) Thyrotropin-releasing hormone (TRH) Thyrotropin-releasing hormone (TRH) is a tripeptide hypothalamic regulatory hormone that regulates the release of thyroid-stimulating hormone (TSH), as well as prolactin (for breasts growth and milk production during and after pregnancy). To obtain thyrotropin-releasing hormones, 6 pro-TRH peptides have first to be obtained from the larger preproTRH precursor (UniProt: P20396). These octapeptides are then cleaved between Arginine/Glutamine and Glutamine/Lysine residues to release 6 Gln-His-Pro-Gly peptides that will be enzymatically converted in pGln-His-Pro-NH2 peptides (pGln representing pyroglutamine). After TRH maturation (1) in neurons located in the pituitary gland, the hormone will be transported along axons (2) to reach the hypophyseal portal system via exocytosis (3). Once the thyrotrophs reached, thyrotropin-releasing hormone binds TRH-receptor (4) to enable TSH synthesis a